Brokerages Set Marker Therapeutics, Inc. (NASDAQ:MRKR) Target Price at $10.25

Shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) have been assigned an average recommendation of “Buy” from the five ratings firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $10.25.

A number of equities analysts have issued reports on MRKR shares. Zacks Research upgraded shares of Marker Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, November 18th. Wall Street Zen upgraded shares of Marker Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Marker Therapeutics in a research note on Wednesday, October 8th.

Marker Therapeutics Trading Up 6.6%

NASDAQ:MRKR opened at $1.06 on Thursday. Marker Therapeutics has a 12 month low of $0.81 and a 12 month high of $5.95. The stock has a 50 day moving average of $0.97 and a two-hundred day moving average of $1.21. The firm has a market cap of $17.67 million, a P/E ratio of -0.86 and a beta of 1.47.

Marker Therapeutics (NASDAQ:MRKR) last issued its earnings results on Thursday, November 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.57. The business had revenue of $1.23 million during the quarter, compared to the consensus estimate of $0.72 million. Marker Therapeutics had a negative return on equity of 92.35% and a negative net margin of 304.56%. On average, research analysts forecast that Marker Therapeutics will post -0.65 earnings per share for the current year.

Hedge Funds Weigh In On Marker Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC acquired a new stake in shares of Marker Therapeutics during the third quarter valued at about $25,000. Two Sigma Investments LP bought a new position in Marker Therapeutics during the third quarter worth $33,000. Finally, Jane Street Group LLC acquired a new position in shares of Marker Therapeutics in the 2nd quarter valued at about $33,000. Hedge funds and other institutional investors own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.